Revolutionizing Antibody Discovery

Complex antibodies, like multispecifics, are hard to engineer because the relationship between design and function is often non-intuitive. As a consequence, conventional methods are liable to deliver sub-optimal molecules which either fail in the clinic or result in poor patient outcomes.

Introducing EVA™

We’ve developed EVA™ — a highly automated discovery engine that enables the rapid identification and co-optimisation of complex therapeutic antibodies across multiple key properties.

Our platform is both modular and scalable, allowing for the efficient exploration of diverse antibody designs, ensuring that we can meet the specific needs of various therapeutic applications.